Pressure grows on ministers to end secrecy over UK medicines deal with Trump
AI Summary
UK ministers are facing increasing pressure from MPs across multiple parties to release the impact assessment of a recent agreement with the US regarding medicine costs. The deal, made with the previous Trump administration, involves the UK potentially paying more for new medicines and increasing NHS spending on life-extending drugs in exchange for tariff-free pharmaceutical exports to the US. Critics fear the agreement could significantly increase costs for the NHS, potentially costing billions annually by 2035. A cross-party group is meeting to discuss strategies to compel the government to publish its assessment of the deal's potential effects. While the government acknowledges increased costs, particularly after 2029, they have not provided specific figures beyond 2028/29, leading to calls for a transparent, independent impact assessment.
Key Entities & Roles
Keywords
Sentiment Analysis
Source Transparency
This article was automatically classified using rule-based analysis. The political bias score ranges from -1 (far left) to +1 (far right).
Topic Connections
Explore how the topics in this article connect to other news stories